乳腺癌基因组改变与放疗抵抗:ProfiLER 方案分析
该研究纳入 ProfiLER 临床试验中 146 例乳腺癌患者,采用二代测序和比较基因组杂交分析肿瘤基因组改变,回顾性分析其与局部区域复发的关联。结果显示 PIK3CA 突变携带者局部区域无进展生存期显著优于野生型患者(HR 0.27,95%CI 0.12-0.65,P=0.002),多因素分析中 PIK3CA 突变为独立保护因素(HR 0.29,95%CI 0.09-0.99,P=0.047)。
要点
- PIK3CA 突变携带者中位局部区域无进展生存期为 23.6 年,野生型为 9.9 年(HR 0.27,95%CI 0.12-0.65,P=0.002)。
- 多因素分析显示 PIK3CA 突变为局部区域复发的独立保护因素(HR 0.29,95%CI 0.09-0.99,P=0.047)。
- 其他基因突变、扩增或缺失均未发现与局部区域无进展生存期相关。
核心结论
- 在该乳腺癌人群中,PIK3CA 突变与较低的局部复发风险相关,这与近期提示 PIK3CA 参与影响放射敏感性生物学通路的研究一致。
研究设计与样本
- 研究纳入 2013 年至 2016 年间 ProfiLER 临床试验(NC01774409)中 146 例乳腺癌患者的肿瘤样本,采用二代测序和比较基因组杂交检测基因谱。
- 患者及肿瘤特征为回顾性收集,并分析其与基因组重排(突变、扩增、缺失)的关联;仅选择在超过 3% 肿瘤中观察到的基因改变。
主要发现
- 共识别 193 个基因组重排,其中 16 个在超过 3% 的肿瘤中观察到。
- 仅一个基因组改变与局部复发风险有统计学相关性:PIK3CA 突变携带者(n=31,21.2%)的中位局部区域无进展生存期为 23.6 年,而 PIK3CA 野生型患者为 9.9 年(单因素分析 HR 0.27,95%CI 0.12-0.65,P=0.002)。
- 多因素分析中,PIK3CA 突变被确定为局部区域复发的独立保护因素(HR 0.29,95%CI 0.09-0.99,P=0.047)。
- 所有其他突变、扩增或缺失均未发现与局部区域无进展生存期相关。
关键数值与推荐
- PIK3CA 突变携带者(n=31,21.2%)中位局部区域无进展生存期为 23.6 年,PIK3CA 野生型患者为 9.9 年(单因素分析 HR 0.27,95%CI 0.12-0.65,P=0.002)。
- 多因素分析中 PIK3CA 突变为局部区域复发的独立保护因素(HR 0.29,95%CI 0.09-0.99,P=0.047)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Breast cancer (BC) patients with comparable prognostic features have heterogeneous outcomes, party related to a possible radiotherapy resistance leading to local-regional recurrences (LRR). The objective of the present study was to identify predictive molecular biomarkers of LRR of BC. PATIENTS AND METHODS: Genetic profile of 146 BC patients' tumours included in the ProfiLER clinical trial (NC01774409) between 2013 and 2016 were analysed using next-generation-sequencing and comparative-genomic-hybridization tests. Patients and tumour characteristics were retrospectively collected and analysed for association with genomic rearrangements (mutations, amplification, deletions). Only gene alterations observed in >3% of the tumours were selected. RESULTS: A total of 193 genomic rearrangements were identified, and 16 were observed in >3% of tumours. One was statistically correlated to the risk of local relapse. A median loco-regional progression-free survival (LRPFS) of 23.6 years was reported for PIK3CA mutation carriers (n = 31, 21.2%) versus 9.9 years for PIK3CA wild-type patients (HR 0.27, 95% CI 0.12-0.65, P = 0.002 in univariate analysis). PIK3CA mutation was identified as an independent protective factor on LRR using multivariate analysis (HR 0.29, 95% CI 0.09-0.99, P = 0.047). All other mutations, amplifications or deletions were not found associated with LRPFS. CONCLUSION: PIK3CA mutation was associated with a lower risk of local relapse in this population of BCs. This is consistent with recent studies suggesting PIK3CA to be part of biological pathways impacting the radiosensitivity.
引用
- Bernichon E, Vallard A, Wang Q, et al. Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol. Ann Oncol. 2017. PMID: 28945826. doi:10.1093/annonc/mdx488
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。